DAX24.217 +1,0%ESt505.379 +0,8%Top 10 Crypto16,34 +2,8%Dow44.633 -0,5%Nas21.098 -0,4%Bitcoin102.279 +0,2%Euro1,1556 +0,1%Öl72,47 -0,4%Gold3.324 -0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Novo Nordisk A3EU6F NVIDIA 918422 Rheinmetall 703000 Heidelberger Druckmaschinen 731400 RENK RENK73 PayPal A14R7U Lufthansa 823212 Mercedes-Benz Group (ex Daimler) 710000 Volkswagen (VW) vz. 766403 Deutsche Bank 514000 BASF BASF11 Tesla A1CX3T DroneShield A2DMAA Amazon 906866 AMD (Advanced Micro Devices) 863186
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Vor Fed-Zinsentscheid: DAX fester erwartet -- Zurückhaltung an Asiens Börsen -- Nach schwächerem 2. Quartal: Mercedes-Benz passt Prognose an -- adidas, BASF, Siemens Healthineers, HSBC, UBS im Fokus
Top News
Reisegigant Booking Holdings stärker denn je! Rekordzahlen, KI-Offensive und ein Reiseerlebnis wie aus einem Guss! Reisegigant Booking Holdings stärker denn je! Rekordzahlen, KI-Offensive und ein Reiseerlebnis wie aus einem Guss!
Allzeithoch in Reichweite: Zündet die Microsoft-Aktie mit den Zahlen am Abend die nächste Kursrakete? Allzeithoch in Reichweite: Zündet die Microsoft-Aktie mit den Zahlen am Abend die nächste Kursrakete?
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Ãœbersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

UCB Aktie

Handeln
UCB Aktien-Sparplan
185,15 EUR +5,45 EUR +3,03 %
FSE
183,20 EUR +2,90 EUR +1,61 %
GVIE
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.33,99 Mrd. EUR

KGV34,29Div. Rendite0,51%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN852738

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINBE0003739530

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolUCBJF

UCB Aktien News

DatumMeistgelesen
PR NewswireUCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa
PR NewswireFDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations
GlobeNewswireUCB Convening Notice to the General Meeting of the Shareholders 2024
PR NewswireFirst Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
PR NewswireBIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count
PR NewswireUCB on Growth Path for a Decade Plus
PR NewswireZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive
PR NewswireUCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting
PR NewswireUCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
PR NewswirePost Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)
PR NewswireUCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023
PR NewswireUCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Founda...
PR NewswireNAYZILAM® (midazolam) Results Published in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters
PR NewswireBIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
PR NewswireUCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis
PR NewswireUCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023
PR NewswirePhase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa
PR NewswireUCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-mu...
PR NewswireUCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis
PR NewswireUCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting
PR NewswireUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance
GlobeNewswireUCB Convening Notice to the General Meeting of theShareholders 2023
PR NewswireBimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks
PR NewswireUCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa
PR NewswireAnnals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis
PR NewswireUCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review
PR NewswireUCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa
PR NewswireThe Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis
PR NewswireUCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care
PR NewswireEpilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)
PR NewswireUCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients
PR NewswireBimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
PR NewswireUCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022
PR NewswireUCB U.S. HEADQUARTERS IN ATLANTA AWARDED PRESTIGIOUS LEED GOLD AND WELL PLATINUM CERTIFICATIONS
PR NewswireUCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting
PR NewswireNew Three-Year Bimekizumab Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis
Dow JonesMÄRKTE EUROPA/Sehr fest dank Aussagen von Fed-Powell
Dow JonesMÄRKTE EUROPA/Sehr fest - Fortum und Uniper mit Kurssprung
Dow JonesMÄRKTE EUROPA/Börsen bauen Gewinne aus
Dow JonesMÄRKTE EUROPA/Freundlich - Entspannung im Umfeld stützt

UCB News

UCB News: auf dieser Seite finden Sie alle UCB News und Nachrichten zur UCB Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch UCB News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um UCB News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.